No-effect level in the mutagenic activity of the drug cyproterone acetate in rat liver: Part I. Single dose treatment

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 550, Issue 1-2, 2004, Pages 89-99

  Topinka, Jan ^a,b   Oesterle, Doris ^a   Reimann, Roland ^c   Wolff, Thomas ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

^c BAYER PHARMA AG   (Germany)

Author keywords

5 bromo 2 deoxyuridine; BrdU; CM; control mutants; CPA; cyproterone acetate; Cyproterone acetate; DNA adducts; MF; mutation frequency; Mutations; Myrj 53; No effect level; PFU; plaque forming unit; polyoxyethylene 50 stearate; TE buffer; Tris EDTA buffer

Indexed keywords

CYPROTERONE ACETATE; MUTAGENIC AGENT;

ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; DNA ADDUCT; DOSE RESPONSE; DRUG EFFECT; FEMALE; LIVER CELL; MUTAGENIC ACTIVITY; MUTAGENICITY; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; RAT; REACTION TIME; SINGLE DRUG DOSE; TIME SERIES ANALYSIS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CYPROTERONE ACETATE; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LIVER; MUTAGENS; MUTATION; RATS; RATS, INBRED F344; TIME FACTORS;

ILEX COOKII;

EID: 2342594381     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2004.02.003     Document Type: Article

References (30)

1. Parry J.M., Jenkins G.J.S., Haddad F., Bourner R., Parry E.M. In vitro and in vivo extrapolations of genotoxin exposures: consideration of factors which influence dose-response thresholds. Mutat. Res. 464:2000;53-63
2. Bentley K.S., Kirkland D., Murphy M., Marshall R. Evaluation of thresholds for benomyl- and carbendazim-induced aneuploidy in cultured human lymphocytes using fluorescence in situ hybridization. Mutat. Res. 464:2000;41-51
3. Elhajouji A., Van Hummelen P., Kirsch-Volders M. Indications for a threshold of chemically induced aneuploidy in vitro in human lymphocytes. Environ. Mol. Mutagen. 26:1995;292-304
4. Elhajouji A., Tibaldi F., Kirsch Volders M. Indications for thresholds of chromosome non-disjunction versus chromosome lagging by spindle inhibitors in vitro in human lymphocytes. Mutagenesis. 12:1997;133-140
5. Sofuni T., Hayashi M., Nohmi T., Matsuoka A., Yamada M., Kamata E. Semi-quantitative evaluation of genotoxic activity of chemical substances and evidence for a biological threshold of genotoxic activity. Mutat. Res. 464:2000;97-104
6. Favor J. The mutagenic activity of ethylnitrosourea at low doses in spermatogonia of the mouse as assessed by the specific locus test. Mutat. Res. 405:1998;221-226
7. Tombolan F., Renault D., Brault D., Guffroy M., Perin-Roussel O., Perin F., Thybaud V. Kinetics of induction of DNA adducts, cell proliferation and gene mutations in the liver of Muta™mice treated with 5, 9-dimethyldibenzo-[c, g]carbazole. Carcinogenesis. 20:1999;125-132
8. Krebs O., Schäfer B., Wolff T., Oesterle D., Deml E., Sund M., Favor J. The DNA damaging drug cyproterone acetate causes gene mutations and induces glutathione-S-transferase P in the liver of female Big Blue™ transgenic F344 rats. Carcinogenesis. 19:1998;241-245
9. Neumann I., Thierau D., Andrae U., Greim H., Schwarz L.R. Cyproterone acetate induces DNA damage in cultured rat hepatocytes and preferentially stimulates DNA synthesis in γ-glutamyltranspeptidase-positive cells. Carcinogenesis. 13:1992;373-378
10. Martelli A., Mattioli F., Fazio S., Andrae U., Brambilla G. DNA repair synthesis and DNA fragmentation in primary cultures of human and rat hepatocytes exposed to cyproterone acetate. Carcinogenesis. 16:1995;1265-1269
11. Topinka J., Andrae U., Schwarz L.R., Wolff T. Cyproterone acetate generates DNA adducts in rat liver and in primary rat hepatocyte cultures. Carcinogenesis. 14:1993;423-447
12. Deml E., Schwarz L.R., Oesterle D. Initiation of enzyme-altered foci by the synthetic steroid cyproterone acetate in rat liver foci bioassay. Carcinogenesis. 14:1993;1229-1231
13. Schuppler J., Günzel P. Liver tumors and steroid hormones in rats and mice. Arch. Toxicol. Suppl. 2:1979;181-195
14. Schulte-Hermann R., Ochs H., Bursch W., Parzefall W. Quantitative structure-activity studies on effects of sixteen different steroids on growth and monooxygenases of rat liver. Cancer Res. 48:1988;2462-2468
15. Heddle J.A., Dean S., Nohmi T., Boerrigter M., Casciano D., Douglas G.R., Glickman B.W., Gorelick N.J., Mirsalis J.C., Martus H.-J., Skopek T.R., Thybaud V., Tindall K.R., Yajima N. In vivo transgenic mutation assays. Environ. Mol. Mutagen. 35:2000;253-259
16. Schulte-Hermann R., Hoffmann V., Parzefall W., Kallenbach M., Gerhard A., Schuppler J. Adaptive response of rat liver to the gestagen and antiandrogen cyproterone acetate and other inducers. II. Induction of growth. Chem. Biol. Interact. 31:1980;287-300
17. Bursch W., Düsterberg B., Schulte-Hermann R. Growth, regression and cell death in rat liver as related to tissue levels of the hepatomitogen cyproterone acetate. Arch. Toxicol. 59:1986;221-227
18. Roberts R., Soames A.R., James N.H., Gill J.H., Wheeldon E.B. Dosing-induced stress causes hepatocyte apoptosis in rats primed by the rodent hepatocarcinogen cyproterone acetate. Toxicol. Appl. Pharmacol. 135:1995;192-199
19. Kasper P., Müller L. Sex-specific induction of apoptosis by cyproterone acetate in primary rat hepatocytes. Carcinogenesis. 20:1999;2185-2188
20. Dycaico M.J., Provost G.S., Kretz P.L., Ransom S.L., Moores J.C., Short J.M. The use of shuttle vectors for mutation analysis in transgenic mice and rats. Mutat. Res. 307:1994;461-478
21. Gupta R.C. Non-random binding of the carcinogen N-hydroxy-2- acetylaminofluorene to repetitive sequences of rat liver DNA in vivo. Proc. Natl. Acad. Sci. U.S.A. 81:1984;6943-6947
22. 32P -postlabeling analysis of aromatic carcinogen adducts Cancer Res. 45:1985;5656-5662
23. Ellwart J., Dormer P. Effect of 5-fluoro-2′-deoxyuridine on 5-bromo-2′-deoxyuridine (BrdUrd) incorporation into DNA measured by a monoclonal BrdUrd antibody and by the BrdUrd/Hoechst quenching effect. Cytometry. 6:1985;513-520
24. Piegorsch W.W., Margolin B.H., Shelby M.D., Johnson A., French J.E., Tennant R.W., Tindall K.R. Study design and sample sizes for lac I transgenic mouse mutation assay. Environ. Mol. Mutagen. 25:1995;231-245
25. Hoorn A.J.W., Custer L.L., Myhr B.C., Brusick D., Gossen J., Vijg J. Detection of chemical mutagens using the Muta™ mouse: a transgenic model. Mutagenesis. 8:1993;7-10
26. Hara T., Hirano K., Tamura H., Sui H., Shibuya T., Hyogo A., Hirashio A., Tokai H., Yamashita Y., Kura K. Mutation induction by N-propyl-N-nitrososureain eight mouse organs. Mutat. Res. 444:1999;297-307
27. Goldsworthy T.L., Recio L., Brown K., Donehower L.A., Mirsalis J.C., Tennant R.W., Purchase I.F.H. Transgenic animals in toxicology. Fund. Appl. Toxicol. 22:1994;8-19
28. Shaver-Walker P.M., Urlando C., Tao K.S., Zhang X.B., Heddle J.A. Enhanced somatic mutation rates induced in stem cells of mice low chronic exposure to ethylnitrosourea. Proc. Natl. Acad. Sci. U.S.A. 92:1995;11470-11474
29. Heddle J.A., Martus H.J., Douglas G.R. Treatment and sampling protocol for transgenic mutation assays. Environ. Mol. Mutagen. 41:2003;1-6
30. ® transgenic system are primarily mouse derived. Mutat. Res. 436:1999;11-19